302 related articles for article (PubMed ID: 15701215)
1. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Zammit GK; McNabb LJ; Caron J; Amato DA; Roth T
Curr Med Res Opin; 2004 Dec; 20(12):1979-91. PubMed ID: 15701215
[TBL] [Abstract][Full Text] [Related]
2. A polysomnography study of eszopiclone in elderly patients with insomnia.
McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
[TBL] [Abstract][Full Text] [Related]
3. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Rosenberg R; Caron J; Roth T; Amato D
Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290
[TBL] [Abstract][Full Text] [Related]
4. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
[TBL] [Abstract][Full Text] [Related]
5. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T
Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910
[TBL] [Abstract][Full Text] [Related]
6. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
Scharf M; Erman M; Rosenberg R; Seiden D; McCall WV; Amato D; Wessel TC
Sleep; 2005 Jun; 28(6):720-7. PubMed ID: 16477959
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
[TBL] [Abstract][Full Text] [Related]
8. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Najib J
Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
[TBL] [Abstract][Full Text] [Related]
10. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
[TBL] [Abstract][Full Text] [Related]
11. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
12. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Boyle J; Trick L; Johnsen S; Roach J; Rubens R
Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
[TBL] [Abstract][Full Text] [Related]
13. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T
Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264
[TBL] [Abstract][Full Text] [Related]
14. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder.
Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H
Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438
[TBL] [Abstract][Full Text] [Related]
15. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study.
Spierings EL; McAllister PJ; Bilchik TR
Cranio; 2015 Apr; 33(2):115-21. PubMed ID: 25323219
[TBL] [Abstract][Full Text] [Related]
17. Eszopiclone for the treatment of insomnia.
Scharf M
Expert Opin Pharmacother; 2006 Feb; 7(3):345-56. PubMed ID: 16448328
[TBL] [Abstract][Full Text] [Related]
18. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial.
Tek C; Palmese LB; Krystal AD; Srihari VH; DeGeorge PC; Reutenauer EL; Guloksuz S
Schizophr Res; 2014 Dec; 160(1-3):180-5. PubMed ID: 25454802
[TBL] [Abstract][Full Text] [Related]
19. Eszopiclone versus zopiclone in the treatment of insomnia.
Pinto LR; Bittencourt LR; Treptow EC; Braga LR; Tufik S
Clinics (Sao Paulo); 2016 Jan; 71(1):5-9. PubMed ID: 26872077
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
